Beth Israel Hospital

Nereid Therapeutics Appoints Michael Kauffman as CEO

Retrieved on: 
Monday, November 13, 2023
Epix Pharmaceuticals, Research, Organization, Johns Hopkins, Therapy, Onyx Pharmaceuticals, MGM+, Biotechnology, Hospital, Verastem Oncology, EMA, Patient, Doctor of Philosophy, Takeda Oncology, Conference, Harvard Medical School, Drug discovery, Cancer, CMO, ATP, Beth Israel Hospital, Massachusetts General Hospital, Coronavirus Scientific Advisory Board, Amgen, Pharmaceutical industry, Nereids, Biogen

BOSTON, Nov. 13, 2023 /PRNewswire/ -- Nereid Therapeutics, a biotechnology company that is discovering new disease treatments by applying pioneering research and technologies to biomolecular condensates, announced today that Michael Kauffman, M.D., Ph.D., has joined the company as President and Chief Executive Officer. Dr. Kauffman will also join the Nereid Board of Directors. Spiros Liras, Ph.D., a venture partner at Apple Tree Partners (ATP) who has been acting CEO of Nereid since the company was created by ATP in late 2020, will continue to serve on Nereid's Board of Directors and the company's Scientific Advisory Board.

Key Points: 
  • Dr. Kauffman will also join the Nereid Board of Directors.
  • "Michael brings to Nereid the right energy at the right time.
  • He currently chairs the boards of BiVictriX Therapeutics and Incendia Therapeutics and serves on the Boards of Verastem Oncology, Kezar Life Sciences, and Adicet Bio.
  • Dr. Kauffman and other members of the Nereid leadership team will be onsite for meetings at the 42nd Annual J.P. Morgan Healthcare Conference taking place January 8-11, 2024, in San Francisco, CA.

BD Names Joanne Waldstreicher to Board of Directors

Retrieved on: 
Monday, July 24, 2023
Bioethics, Endocrinology, Internal medicine, Ronald Reagan Presidential Library, University School, Health, Research, Medicine, Jeff Waldstreicher, Merck & Co., Harvard Medical School, J&J, Becton, Dickinson and Company headquarters, Chemistry, Development, Retirement, Publication, Beth Israel Hospital, Metabolism, Division, Population health, Medical ethics, Hospital, Johnson & Johnson, Becton, Biostatistics, FDA, Massachusetts General Hospital, Regulation of tobacco by the U.S. Food and Drug Administration, Epidemiology, BDX, NYSE, Medtech, Food, Safety, BD, Management, Pharmaceutical industry, Brooklyn College

FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors.

Key Points: 
  • FRANKLIN LAKES, N.J., July 24, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne Waldstreicher to its board of directors.
  • Waldstreicher, 63, was most recently the chief medical officer for Johnson & Johnson (J&J), serving in this capacity from 2012 until her retirement in 2023.
  • Prior to being named chief medical officer for J&J, Waldstreicher served as chief medical officer for Janssen Pharmaceutical Research and Development, which is a division of J&J, from 2009 to 2012.
  • Waldstreicher earned a bachelor's degree in chemistry from Brooklyn College and her doctor of medicine from Harvard Medical School.

Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Wednesday, July 19, 2023
Biotechnology, Pharmaceutical, Health, Neurology, Merit Cudkowicz, International, Harvard–MIT Program in Health Sciences and Technology, Life, Outline of health sciences, Clinical trial, American Academy, Boston, COYA, Forbes Norris, Harvard Medical School, National Institute of Neurological Disorders and Stroke, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, DSM-IV codes, Massachusetts Institute of Technology, Public health, Beth Israel Hospital, Patient, Coya, Chemical engineering, Master of Science, Hospital, American Academy of Neurology, Massachusetts General Hospital, Therapy, ALS, Harvard School of Dental Medicine, Commerce, Pharmaceutical industry, MD

Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.

Key Points: 
  • Dr. Cudkowicz is a world-renowned neurologist who has dedicated her career to improving the life of patients with ALS and other serious neurological conditions.
  • Dr. Cudkowicz brings decades of experience supporting the development of new therapies for ALS.
  • Dr. Cudkowicz has launched the first platform trial initiative in ALS, the HEALEY ALS Platform Trial, a program that helps accelerate therapy development in ALS.
  • Merit Cudkowicz commented: "I am happy to join Coya as a clinical advisor as they move COYA 302 into a well powered and designed clinical trial.

Susan M. Love, MD, MBA, Chief Visionary Officer and "Founding Mother" of Breast Cancer Advocacy and Research Dies

Retrieved on: 
Monday, July 3, 2023
President Clinton, Volunteering, Love, Executive, Surgeon, Fordham University, University, Army, Brigham and Women's Faulkner Hospital, Parent, State university system, Radiology, National Breast Cancer Coalition, Anderson School, Marriage, Woman, MBA, Research, History, Alpha Omega Alpha, Young Survival Coalition, Movement, HRT, NBCC, SUNY Downstate Medical Center, Beth Israel Hospital, International Symposium on Endovascular Therapy, MD, Breast cancer, The New York Times, Patient, Notre Dame, Revlon, Breast, Supreme court, School Sisters of Notre Dame, LOS, AI, Oncology, UCLA, State University of New York Upstate Medical University, Leukemia, Mammography, NIH, Hormone replacement therapy, Birth control, Medical device

LOS ANGELES, July 3, 2023 /PRNewswire/ -- Susan M. Love, MD, MBA, who led Dr. Susan Love Foundation for Breast Cancer Research since 1995, steering the Foundation through its innovative and life-changing research and advocacy programs, has died. She was 75.

Key Points: 
  • She was an early advocate of cancer surgery that conserves as much breast tissue as possible.
  • A founder of the breast cancer advocacy movement in the early 1990's, she helped organize the National Breast Cancer Coalition (NBCC) .
  • As Founder and Chief Visionary Officer of the Dr. Susan Love Foundation for Breast Cancer Research, Dr. Love built and oversaw an active research program centered on the cause and prevention of breast cancer.
  • The Love Research Army, which she launched in 2008, creatively accelerated cancer research by partnering volunteers and scientists for clinical trials and cancer research.

Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer

Retrieved on: 
Monday, June 5, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Vaccine, SUNY Downstate Medical Center, University, Metabolism, Vaccination, Rochester, Multimedia, Temperature, Harvard Medical School, Type 2, Beth Israel Hospital, MD, III, Clinical, Pfizer, Pharmaceutical industry, Chemistry

Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.

Key Points: 
  • Vaxxas , a clinical-stage biotechnology company commercializing a novel vaccination platform technology, today announced the appointment of Rochelle Chaiken, M.D., as Chief Medical Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230605005170/en/
    Vaxxas CMO Rochelle Chaiken MD (Photo: Business Wire)
    Reporting to Vaxxas Chief Executive Officer David Hoey, Dr. Chaiken will be a valuable addition to the Vaxxas leadership team as the company advances its proprietary high-density microarray patch (HD-MAP) technology platform through late-stage clinical studies towards commercialization.
  • Dr. Chaiken held a number of senior executive roles at Pfizer including, for the past five years, Chief Medical Officer for the company’s Biopharmaceutical Group for Emerging Markets.
  • “We are delighted to welcome Rochelle to the Vaxxas team as Chief Medical Officer at this pivotal time for the business, as we advance our vaccine patch technology through multiple development programs with multiple respective vaccines and partners,” said David Hoey, Vaxxas CEO.

DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Retrieved on: 
Tuesday, May 30, 2023
FDA, Health, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Chief scientific officer, Collateral circulation, DMAC, University, Senior, Internal medicine, Patient-Centered Outcomes Research Institute, Harvard T.H. Chan School of Public Health, Stroke, TPA, Harvard University, Associate, Bangladesh Technical Education Board, Harvard Medical School, NYSE, Master of Science, Public health, Miami University, Publication, National academy, Beth Israel Hospital, Patient, Division, Neuromodulation, PCORI, Executive Committee, Case Western Reserve University School of Medicine, S-1 Executive Committee, Biostatistics, HEAL, Neurology, NIH, Interventional cardiology, Pharmaceutical industry, Nursing, Science, Medtronic, Brigham, Parkland Memorial Hospital, Medicine

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.
  • Dr. Richard Kuntz recently retired from Medtronic plc (NYSE:MDT) where he was the Chief Medical Officer & Scientific Officer and a member of the Executive Committee.
  • Prior to that, he served as Senior Vice President and President, Neuromodulation of Medtronic from October 2005 to August 2009.
  • Before joining Medtronic, he was the founder and Chief Scientific Officer of the Harvard Clinical Research Institute in Boston.

The Inner Circle Acknowledges, William A. Calabria as a Top Pinnacle Healthcare Professional for his contributions to the field of Osteopathic Medicine

Retrieved on: 
Friday, May 19, 2023
Newark Beth Israel Medical Center, Osteopathic medicine in the United States, Emergency medicine, Internal medicine, Physician, AOBIM, Rowan-Virtua School of Osteopathic Medicine, Monmouth University, Mentorship, American Osteopathic Association Bureau of Osteopathic Specialists, Inner circle, American Osteopathic Board of Internal Medicine, American Osteopathic Association, Patient, CaroMont Regional Medical Center, Doctor of Osteopathic Medicine, Diagnosis, ICU, Sports medicine, Disease, Veterinary medicine, Science, Beth Israel Hospital, MD, Biology

GASTONIA, N.C., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, William A. Calabria is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Osteopathic Medicine.

Key Points: 
  • GASTONIA, N.C., May 18, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, William A. Calabria is acknowledged as a Top Pinnacle Healthcare Professional for his contributions to the field of Osteopathic Medicine.
  • Dr. Calabria began his educational journey at Monmouth University where he earned a Bachelor of Science in Biology.
  • He then graduated with his Doctor of Osteopathic Medicine degree from Rowan University School of Osteopathic Medicine in 2000 and completed a residency in emergency medicine at Newark Beth Israel Medical Center in 2002.
  • He completed a second residency in internal medicine and emergency medicine, and a fellowship in sports medicine at St. Barnabas Medical Center/Newark Beth Israel Hospital.

Endogenex™ Appoints Christopher Sorli as Chief Medical Officer

Retrieved on: 
Thursday, May 18, 2023
Men's Health, Medicine, DSM-IV codes, Insulin, Obesity, University, Billings, Montana, Metabolism, Type 2 diabetes, Billings Clinic, Duodenum, Quality of life, CMO, Priscilla Chan, Graduate, Type 2, Blood, Beth Israel Hospital, Patient, Metabolic syndrome, Single-use medical devices, Sanofi, FDA, Health, T2D, Safety, Pharmaceutical industry, Nursing, Medical device, Endocrinology, Diabetes

MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Christopher Sorli, M.D., Ph.D., as Chief Medical Officer (CMO). Dr. Sorli brings a wealth of experience and clinical expertise to the company's leadership team further strengthening Endogenex's commitment to innovation that drives improvement in patient outcomes. As CMO, Dr. Sorli will play a pivotal role in shaping Endogenex's strategic medical vision and draw upon an extensive clinical background to lead medical affairs activities, collaborate with regulatory agencies, and establish relationships with healthcare professionals and patients that will advance Endogenex's position in the medical device industry.

Key Points: 
  • Bringing expertise in diabetes management, medical and regulatory affairs, clinical research, and market access
    MINNEAPOLIS, May 18, 2023 /PRNewswire/ -- Endogenex, Inc., a clinical stage medical device company, is proud to announce the addition of Christopher Sorli, M.D., Ph.D., as Chief Medical Officer (CMO).
  • Dr. Sorli joins Endogenex from Acerus Pharmaceutical where he was Chief Medical Officer leading the development of products that improve patient experience, with a primary focus in the field of Men's Health.
  • Dr. Sorli was also the Vice President and Head of Diabetes for US Medical at Sanofi where he led US medical strategy and medical activities for established and developmental portfolios of diabetes products.
  • Dr. Sorli also led The Center of Excellence in Diabetes and Metabolism, a clinical research center and metabolic surgery program.

Cambia Health Solutions appoints Donna L. Milavetz, MD, MPH as chief medical officer

Retrieved on: 
Tuesday, October 18, 2022
Salt Lake, Commerce, Mayo Clinic, Clinical professor, Public health, University of Minnesota School of Nursing, Cambia Health Solutions, FACP, MPH, Beth Israel Hospital, Multimedia, Internal medicine, University, Fortis Healthcare, Public, Steward Health Care System, Health, Harvard University, University of Arizona College of Medicine – Tucson, Jewish Board of Family and Children's Services, View, University of Minnesota School of Public Health, Medicine, Management, MD

PORTLAND, Ore., Oct. 18, 2022 /PRNewswire/ -- Cambia Health Solutions is pleased to announce Donna L. Milavetz, MD, MPH, FACP as chief medical officer.

Key Points: 
  • PORTLAND, Ore., Oct. 18, 2022 /PRNewswire/ -- Cambia Health Solutions is pleased to announce Donna L. Milavetz, MD, MPH, FACP as chief medical officer.
  • "Since Dr. Milavetz joined Cambia as executive medical director earlier this year, she has established herself as an entrepreneurial and collaborative leader," said Jared Short, Cambia's chief executive officer.
  • She founded and led Onsite Care, Inc. as its chief executive officer and chief medical officer for more than a decade.
  • "I am honored to take on this role at such an exciting time for Cambia and the health care industry," said Dr. Milavetz.

EDGC (Eone Diagnomics Genome Center) recruits Sam Martin, Vice President of Overseas Business Development... to "accelerate entering the overseas market"

Retrieved on: 
Tuesday, September 13, 2022
Precision medicine, Genetic counseling, Beth Israel Hospital, Liquid biopsy, Industry, Genetics, Cancer, Non-functional testing, GenomeWeb, Technology, Diagnosis, SAN, Multimedia, Video game, Invitae, American, KOSDAQ

By recruiting Sam Martin, who has a wealth of experience and network in the overseas genome market, EDGC will make a full-scale entry into overseas markets and solidify its status as a global bio company.

Key Points: 
  • By recruiting Sam Martin, who has a wealth of experience and network in the overseas genome market, EDGC will make a full-scale entry into overseas markets and solidify its status as a global bio company.
  • Sam Martin is an American Board-Certified Genetic Counselor who holds multiple master's degree in human genetics/genetic counseling and software engineer and design from the United States.
  • He recently worked for Invitae and Ambry genetics, two of the top US genetics companies specializing in personal genomic medicine.
  • He also has clinical experience as a genetic counseling, working eight years at Beth Israel Hospital in New York City.